Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors

In a single-group trial, 352 patients with acute major bleeding while taking a factor Xa inhibitor were treated with andexanet. Andexanet markedly reduced anti–factor Xa activity, and 82% of the patients had excellent or good hemostatic efficacy at 12 hours.

Uložené v:

Podrobná bibliografia
Vydané v:	The New England journal of medicine Ročník 380; číslo 14; s. 1326 - 1335
Hlavní autori:	Connolly, Stuart J, Crowther, Mark, Eikelboom, John W, Gibson, C. Michael, Curnutte, John T, Lawrence, John H, Yue, Patrick, Bronson, Michele D, Lu, Genmin, Conley, Pamela B, Verhamme, Peter, Schmidt, Jeannot, Middeldorp, Saskia, Cohen, Alexander T, Beyer-Westendorf, Jan, Albaladejo, Pierre, Lopez-Sendon, Jose, Demchuk, Andrew M, Pallin, Daniel J, Concha, Mauricio, Goodman, Shelly, Leeds, Janet, Souza, Sonia, Siegal, Deborah M, Zotova, Elena, Meeks, Brandi, Ahmad, Sadia, Nakamya, Juliet, Milling, Truman J
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Massachusetts Medical Society 04.04.2019
Predmet:	Acute Disease Aged Aged, 80 and over Anticoagulants Atrial Fibrillation - drug therapy Bleeding Cardiovascular diseases Coagulants - therapeutic use Drug dosages Enrollments Factor Xa - therapeutic use Factor Xa Inhibitors - adverse effects Factor Xa Inhibitors - metabolism Factor Xa Inhibitors - therapeutic use FDA approval Female Gastrointestinal Hemorrhage - chemically induced Gastrointestinal Hemorrhage - drug therapy Hemoglobin Hemorrhage Hemorrhage - chemically induced Hemorrhage - drug therapy Hemostasis Human health and pathology Humans Intracranial Hemorrhages - chemically induced Intracranial Hemorrhages - drug therapy Life Sciences Male Medical research NMR Nuclear magnetic resonance Patients Pharmaceuticals Recombinant Proteins - therapeutic use ROC Curve Canada United States > US
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	In a single-group trial, 352 patients with acute major bleeding while taking a factor Xa inhibitor were treated with andexanet. Andexanet markedly reduced anti–factor Xa activity, and 82% of the patients had excellent or good hemostatic efficacy at 12 hours.
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa1814051